H IP FRACTURE is a serious health problem in the geriatric population. It is associated with devastating consequetices for both ihe individual and the healthcare system. In many cases, a hip fracture heralds the beginning of a stidden and dramatic series of lifechanging events with undesirable outcomes, such as instittitionalization and death. Over 350,000 hip fracttires occur annually in the United States.' Cxnsus trends indicate that the fastest rate of growth in the older population is occurring in the oldest age group, those more than 85 years old and most susceptihle to hip fracture." Since hip fracture rates double with every 5 years' increase in age, it is alarming, but not surprising, then, that some have estimated that by 2040 the annual number of hip fractures in the llnited States will exceed 500,000.^ ' By 90 years of age, 1 in 4 women and 1 in 8 men will have fractured a It is hoped that the future of hip fracture incidence may be altered as osteoporosis awareness, primary prevention, and the availability of bisphosphonates and other pharmacologic interventions become more pervasive. Fall-prevention programs through exercise. risk factor reduction, and environmental design are helpful, too. However, for those with significant bone loss who are unexposed or intolerant to osteoporosis treatments, for those in whom all falls cannot be eliminated, or for those seeking an adjunct measure for hip fracture prevention, external hip protectors (EHPs) (Figs 1 and 2) offer an additional strategy for the intervention in the prevention of liip fractures.
HIP FRACTURE OUTCOMES

Mortality
In the year following a hip fracture, mortality from any cause is about 24%. with higher rates of death observed in older, male and nursing home (NH) populations.'^' In one study, across all categories of locomotor. selfcare, sphincter control, and transfer abilities, mortality was highest in the most functionally dependent groups as compared to the most functionally indepetident groups (with up to 2 times higher risk of death).' Nursing home residence is associated with higlier baseline ftinctional impairment, fniiltj; and comorbid disease, which contribute to mortality rates that can be almost twice as high as that in Figure 2 . Soft shell hip protector (http://hipsaver. com). community dwellers.^-^ Not only are the consequences of hip fracture more dire in NH residetits, but also the risk of hip fracture is up to 11 times higher.*^"'" Mortality estimates specifically attributable to hip fracture are much lower. For example, although 1-year mortality from ail causes is as high as 6()% in male NH residents more than 85 years old, it is only as high as 18% for hip-fracturespecific monatity in tliis group.*' Age-specific trends show that hip fracture mortalit)' increases with age, also iikely a function of overall compromised health status/'''
Morbidity
Even if an individual survives a hip fracture, a significant deterioration in functional status is very common. Functional recovery-following hip fracture typically reaches a plateau by 6 months.*^"" '-' -^ For community-dwelling individuals, after a hip fracture, the mean increase in number of difficulties with basic activities of daily living (BADLs) is 1.12 (P < .0001).'" Age more than 85 years, cognitive deficits, a more complicated medical course, and having lived alone before a fracture are predictors for failing to regain BADLs at 1 year after a hip fracture.'*'^ Less than half of surviving patients who have sustained a hip fracture achieve their previous walking ability.'-^ '^"^"'" More than half of patients previously able to climb stairs independently are unable to do so after a hip fracture.Â dvanced age, female gender, dementia, and ambulation without an assistive device prior to the fracture are each associated with decreased ability to regain premorbid level of ambulatory independence.'N ew physical impairments and increased dependence on others have ramifications on the psychological well-being of patients with hip fracture. One study found that 1 year after a hip fracture, the percentage of homebound subjects doubled from 23% to 46%.'*' Another study showed that only 26% of hip fracture victims had regained their previous social role.^ Assessments of health-related quality of life reveal that both physical and social domains are severely affected in the months after a fracture."' '"'
In 1994, the Office of Technoiijgy Assessment (OTA) estimated that within the year of sustaining a hip fracture. 5% to 10'!.-of patients require rehospitalization for a fracturerelated issue.'' Moreover, the risk of a second hip fracture is up to 9 times more in men and 6 times more in women than the risk of first fracture.^*'"^' Usually, the second fracture involves the contralaterai hip.-" -'
Instltutionalization
After a hip fracture, many patients are discharged to a NH for a course of rehabilitation prior to returning home. However, between 20% and 57% of patients may remain in the NH for more than I year.''" '"^^ Factors predicting permanent NH residence following a hip fracture in the communit) include older age, being single, non-white, having lower per capita income, dementia, ambulatory dependence, and incontinence."' "^ For patients entering a NH subsequent to a hip fracture, the OTA ccmcluded that length of stay beyond I year should not be attributed to the hip fracture. They determined that the need for permanent long-term care in these cases is likely due to factors that are not the direct consequence of the fracture, but rather are caused by patient-related factcjrs (frailty, dementia, poor social supports) tbat eventually would have led to permanent institutionalization within that time horizon.''
Costs
As ihe population ages and the number of hip fractures rises rapidly, a serious economic burden looms. Some authors have suggested that by 2040 bip fractures will exceed 500.000 per year, with costs surpassing $16 billion in the United States,-' In 1994. 6-monih total Medicare payments per hip fracture patient were S23.5(K).''' In the Baltimore Hip Fracture Study, the estimated cost directly attributable to tlie hip fracture exceeded $16,000; hospitalization, NH. and rehabilitation costs comprised most of this value.'*' An estimate of the 1-year direct costs of osteoporosis-related hip fractures sustained in the United States in 1995 was S8.6H billion, (jf which 95% was devoted to inpatient and NH care.-If nursing home stays longer than I year are considered to be hip-fracture-related, the OTA estimated that the total cost for the long-term care of patients with hip fracture was $93,878 per person in 1990 US dollars.
HIP FRACTURE PREVENTION
The prevention of hip fractures involves a 3-pronged strategy to increase bone mineral density, to reduce the number of falls, and to minimize the force of a fall s impact with hip padding. The first 2 modalities may have limited effectiveness for some, particularly the oldest old. who are also at the higliest risk of hip fracture. However, if the bones cannot be strengthened and the falls cannot be completely eliminated, the final defense is to protect the bone and reduce the impact of direct trauma. It is noteworthy that strengthening bones and reducing falls benefit all fall-related fractures, but shielding the hip does not reduce fracture risk to other bones.
Osteoporosis treatments
CAirrently. there are many pharmacologic interventions that are used to improve bone mineral densit) (HMD). Foremost, adequate dietarv' or supplemental calcium provides the building blocks without which any medication to build bone is useless. Vlianiin D impmves absorption of calcium and is often insufficient in older homebound patients with poor diets and low sun exposure. At recommended doses, there are few side effects except constipation (approximately 15% vs 9% with placebo). High doses of calcium are associated with kidney stones and renal damage resulting from hypercalcemia.^" Ustrogen replacement therapy (ERT) has Fcxxl and Drug Administration (TDA) approval for osteoporosis prevention. Hormone replacement therapy (HRT) tjpicaily involves combined estrogen and progestin therapy, as the latter is added to reduce the risk of endometrial cancer observed with unopix)scd estrogen: it is not needed after a hysterectomy. Althoujih estrogen has important benefits to multiple organ systems, its use has hecome contrcA'ersial in the management of osteoporosis prevention in women without other indications for estrogen replacement. The Women s Health Initiative trial was stopped early, when an increased risk of cardiovascular disease, stroke, invasive hreast cancer, and venous thr(.)mboeniholic disease was observed."' The benefits of ERT/HRT seem greatest when initiated soon after menopause and if taken for more than 10 years. However, only 50% of patients remain on therapy at 1 year^** In addition, bone loss accelerates to reach untreated levels if therapy is discontinued. For the treat in en t of osteoporosis in women using ERT/HRT for other indieations, ctimbination therapy with a hisphosphonate is advised."** Bisphosphonates are considered first-line therapy in the prevention and treatment of osteoporosis.-'' The Fracture Intervention Trial (FIT) showed that alendronate reduced the risk of hip fractures by Sl'^.. in severely osteoporotic patients.**' In another study, risedronate decreased the risk of hip fracture hy 50'>n.^' Gastrointestinal side effects are similar to that from placebo; however, there have been rare eases of severe esophageal ulceration."" Administration may be difficult for individuals who cannot drink a ftill glass of water or remain fasting and upright for I'/z hour after taking the medication. Once-a-week dosing may attenuate this problem. Since bisphosphonate half-life in the bone is prolonged, accelerated bone loss is not observed for at least 2 years after the treatment is discontinued."** Raloxifene is the only Selective Estrogen Receptor Modulator (SERM) approved for use in the prevention and treatment t)f osteoporosis. It is a second-line agent when bisphosphonates are contraindicated. In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. BMI) at the hip and spine increased by 2% to 3%; however, hip fracture reduction has not been shown."' Although niloxifene may have a lavorable impact on both breast cancer and low-densit>' lipoprotein (LDL) concentrations, it has a risk of venous tbromboembolism that is commensurate with estrogen thcnipy."''
Most of the evidence supporting calcitonin for osteoporosis treatment is indirectbased on improvements in BMI) at sites other than the hip."" Although it is considered a third-line therapy, ealcitonin appears to have some analgesic effects that ma\ he particularly helpful in the acute management of patients with painful vertebral fractures unresponsive to traditional analgesics."'-*-Calcitonin has the fewest side effects when administered in the intnmasal form, although local irritation, flushing, diuresis, headache, and vomiting may still occur.''* If used for pain, ealcitonin can be used in combination with a bisphosphonate.
Parathyroid liormone (PTH) is the only anabolic agent that is FDA-approved for the management of osteoporosis. Hip fracture data are not availahle. Intermittent dt)sing, as a daily injection, stimulates osteoblastic activity and high-quality bone formation. There are still unresolved long-term safety issues, as rats have developed osteosarcomxs at high doses. In this. PTH injections should be reserved for individuals who have severe, recalcitrant osteoporosis or who cannot tolerate the antiresorptive therapies. Currently, therapy is not recommended heyond 2 years."' Fluoride is not recommended for the treatment of osteoporosis. Some studies have shown an increase in fractures, perhaps because the quality of bone is abnormal (Table 1) .^**
Fall prevention
Reducing environmental hazards, accommodating physical limitations, and addressing patient-specific needs are important steps to reducing falls. A Cochrane Review (jf falls prevention in the elderly assessed 62 studies and performed meta-analyses on comparable interventions." The authors concluded that the interventions most likely to reduce falls were those that were multidisciplinarv. multifactorial programs that screened for and 
External hip protectors
Despite pharmacologic interventions to prevent or treat osteoporosis and programs to minimize falls, the effectiveness of these modalities may be assuaged by medication intolerance, polypliarmacy issues, side effects, time lag tor effect on bone density, dementia, and irreversibility of some conditions impairing balance and gait, EHPs provide a complementary approach to hip fracture prevention.
Initial investigations involving a tall simulation experiment using 20 mm and 29 mm of porcine soft tissue showed that tbe thicker layer absorbed 60% more energy of impact. A 10-mm-thick polystjrene tbam layer tested provided similar reductions in force.^^ From this was conceived the notion of providing an external protective .sbield over tbe vulnerable trochanters to reduce tbe impact of a fall and hence the risk of hip fracture. Over the past decade, multiple clinical trials of various EHPs designs have demonstrated that EHPs can reduce hip fracture incidence with immediate efficacy, unlike pharniacologic therapies for osteoporosis. A recent study measuring the force of a fall in normal volunteers showed that both high-and Unv-dcnsity pads attenuated the energy transmitted to the trochanter well helow the level required to fracture an osteoporotic hip in cadavers.^" EHPs consist of 2 simple padding-or shieldlike devices, secured to an undergarment over each of the trochimters. EHPs work by shunting or absorbing the force of impact during a fall. Hard-shell EHPs are constructed of a plastic polymer and shunt the energy of a fall to the surrounding soft tissues (Fig 2) . Soft-shell EHPs are composed of special foam-like materials that absorb the energy of the fall, such that the force transmitted to the irochanter is significantly diminished. There are many manufacturers with different versions based on lhe.se 2 mechanisms (Figs 1 and 2) . Not all hip protectors have been studied in clinical research trials, and there are no studies that directly compare different hip protector types in the clinical setting.
On average, a set of 3 garments is replaced yearly at a cost under SlOO per person for the soft-shell variety and under $275 for the hard-shell type. Iliese do not require special care for maintenance, laundering, or application, although incontinence may necessitate more frequent replacement. There are virtually no significuiit side effects related to the shields."
EXTERNAL HIP PROTECTOR OUTCOMES Effectiveness
Over the last 10 years, there have been several clinical trials to study tbe effectiveness of EHPs. Most have occurred outside of the United States and most have investigated the hard-shell variety. Asummaryof the individual studies of the clinical effectiveness of EHPs is shown in Table 2 . Studies in which EHPs were part of a broader fracture prevention effort are not included in the table, as it is difficult to isolate the benefit solely attributable to EHPs in these cases.
Two recent meta-anaiyses have evaluated the effectiveness of EHPs. The first incorponited data from 5 studies and included 3445 subjects in institutional settings. The authors estimated a pooled relative risk for hip fracture reduction of 0.35 (95% Cl: 0.23-0.51) in an intention-to-treat analysis. *" For subjects who adhered to EHPs. the pooled relative risk for hip fracture reduction was 0.04 (95% Cl: 0.01-0.16).*" Criticisms of this stud>' cite that the triai.s included were methodologically flawed by inadequate treatment clusters or the trials made unit of analysis errors.^' The authors have updated their estimate of the relative risk of hip fracture in institutionalized subjects with more recently published randomized controlled trials. The relative risk increased to 0.60 (95% Cl: 0.41-0.88); if only trials with individual randomization were included, the relative risk increased to 0.68 (95% Cl: 0.35-1.31).''Â second meta-analysis by the Cochrane Review included randomized controlled trials with individual randomization in either institutional or community-settings. Tlie pooled relative risk of these 7 studies with 2392 subjects was 0.94 (95% Cl: 0.67-1.31). When limited to the NH/residential care settings (5 studies with 1426 subjects), the pooled relative risk was 0.83 (95% Cl: 0.54-1.24) and when restricted to the community setting (2 studies with 966 participants), it was 1.11 (95% Cl: 0.65-1.90). In this more active population, it is not clear how much an increased confidence due to EHPs may have resulted in subjects engaging in more high-risk activities. Pooling of cluster randomized studies achieved a relative risk of 0.34 (95% Cl: 0.19-0.61).-^'T here have been no clinical trials comparing effectiveness between particular EHP models, which may differ in actual protective benefit (efficacy) and/or adberence patterns. Because adherence with the EHP intervention is often poor, the protective benefit observed in adherers is diluted. In fact, post hoc analyses suggest dramatic hip fracture 290 TOPICS IN GERIATRIC REHABILITATION HIP FRACniRE PREVENTION risk reduction in EHP wearers and underscore the importance of improving adherence to maximize the benefit of EHPs.^^^^ Adherence in the supervised setting of an institution and in the independent community environment are not homogeneous for a multitude of reasotis, which support the separate analysis of such subjects in study design. Essentially, researchers, EHP designers, clinicians, and patients must realize that no EHP can be effective if it is not worn.
Falls self-efficacy
Tails self-tfficacy"^^ is a measure of one's confidence to perform an activity without falling; it may be a better predictor of function than "fear of falling."^"' Both fear and decreased confidence often lead to the s-3 s III 0 £ a. avoidance of activities even if one has no functional restrictions.''•''" Fear of falling is panic iilarly common after a fall, with gait or balance impairment, female gender, cognitive difficulties, or low economic resources.^" While several studies of adherence indicate that "fear of falling" may motivate one's use of EHPs, a study of 1.^1 women with a history of falls showed a statistically significant improvement in fails self<fficacy with EHPs.'''Â dherence Effectiveness of EHPs is undeniahly predicateil on adherence. As discussed earlier, adherence is genenilly poor, regardless of setting. Adherence declines rapidly within the first few months of use and is usually less than one half" to one third of suhjects at 6-months or more.**^'^^-''-^-^***"'^^ Most data on adherence have heen collected as part of effectiveness trials. A diffictilt)' in evaluating adherence across studies is that there is no imiform definition of adherence-For convenience, mlherence is often defined for study purposes as the use of EHPs at the time of a recorded fall. However, some researchers have used logs recorded by patients or caregivers and still others have periodically ascertained use of Table 4 . Cost-effectiveness analyses'" EHPs hy unplanned visits by research staff. To complicate matters, adherence to EHPs may be categorized as percentages of subjects with any use" versus "no use,"or quantified hy the average number of bours worn. See Table 2 for a summary of adherence results as reported in ciinical effectiveness trials and lable .5 for the results in studies that focused on adherence outcomes.
Overall, the causes of poor adherence are muilifactorial. In Nfl environments, instittitionai commitment (widespread use and endorsement of EHPs) and staff education have improved adherence to EHPs in residents.*"''''''^'"^ For independent community-dwellers, focus groups on EHPs revealed concerns about inconvenience, laundering, comfort, appearance, cost, and, interestingly, the lack of personal relevance" acknowledged by subjects wbo were otbcrwise considered at high risk for hip fracture.''^"'^'Ĉ ost-effectiveness Several economic analyses have shown that FHPs are both cost-saving and cost-effective from the societal perspective. 
CONCLUSION
Hip fracture and its consequences are certain to remain critical issues at both clinical and public health levels. Prevention and treatment of osteoporosis as well as fall prevention strategies may be complemented by the implementation of EHPs in certain individuals, particularly tliose in the institutional setting. Although the body of evidence regarding the effectiveness of EHPs is equivocal, it is complicated by poor adherence, especially in mixed populations with varying degrees of supervision or where personal esthetics may supercede clinical imperatives. Targeting EHPs at individuals with the highest risks and witb more supervision will ensure that the benefits of EHPs are maximized, reducing morbidity, mortalitv, and costs.
